Investigational Drug Details
| Drug ID: | D495 |
| Drug Name: | Glycerin |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB09462 |
| DrugBank Description: | A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism. |
| PubChem ID: | 753 |
| CasNo: | 56-81-5 |
| Repositioning for NAFLD: | Yes |
| SMILES: | OCC(O)CO |
| Structure: |
|
| InChiKey: | PEDCQBHIVMGVHV-UHFFFAOYSA-N |
| Molecular Weight: | 92.0938 |
| DrugBank Targets: | Peroxisome proliferator-activated receptor delta; Group IIE secretory phospholipase A2; Inositol-3-phosphate synthase 1; Alcohol dehydrogenase 1B; Inositol 1,4,5-trisphosphate receptor type 1; Glycodelin; Alpha-N-acetylgalactosaminidase; ADP-ribosylation factor 1; Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1; DNA mismatch repair protein MutL; Ribonucleoside-diphosphate reductase 1 subunit beta; A/G-specific adenine glycosylase; tRNA (cytosine(38)-C(5))-methyltransferase; Maleylacetoacetate isomerase |
| DrugBank MoA: | When administered rectally, glycerin exerts a hygroscopic and/or local irritant action, drawing water from the tissues into the feces and reflexively stimulating evacuation. Glycerin decreases intraocular pressure by creating an osmotic gradient between the blood and intraocular fluid, causing fluid to move out of the aqueous and vitreous humors into the bloodstream. |
| DrugBank Pharmacology: | Glycerin is commonly classified as an osmotic laxative but may act additionally or alternatively through its local irritant effects; it may also have lubricating and fecal softening actions. Glycerin suppositories usually work within 15 to 30 minutes. |
| DrugBank Indication: | It is used as a solvent, emollient, pharmaceutical agent, and sweetening agent. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0282 | NCT04192110 | PHASE4 | WITHDRAWN | NO | 2020-08-11 | 2021-12-09 | Details |
| L0676 | NCT00384657 | PHASE3 | WITHDRAWN | NO | 2008-01 | 2017-12-22 | Details |
| L1260 | NCT04575896 | PHASE4 | COMPLETED | YES | 2020-11-20 | 2024-01-10 | Details |
| L1281 | NCT00532688 | PHASE2|PHASE3 | UNKNOWN | NO | 2007-09 | 2007-09-20 | Details |
| L1648 | NCT01167309 | PHASE1 | COMPLETED | NO | 2010-06 | 2025-02-24 | Details |
| L2515 | NCT02401880 | PHASE4 | COMPLETED | NO | 2015-05 | 2016-02-24 | Details |
| L2859 | NCT05443568 | ENROLLING_BY_INVITATION | NO | 2023-03-09 | 2023-12-26 | Details | |
| L3652 | NCT01910246 | PHASE4 | WITHDRAWN | NO | 2015-04 | 2018-12-11 | Details |
| L5728 | NCT03313752 | PHASE3 | UNKNOWN | NO | 2017-12-01 | 2021-03-03 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|